Adell Harriman & Carpenter’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$42.9M Buy
170,667
+855
+0.5% +$184K 2.2% 10
2026
Q1
$36.9M Sell
169,812
-880
-0.5% -$195K 2.25% 9
2025
Q4
$39M Buy
170,692
+1,596
+0.9% +$364K 2.33% 11
2025
Q3
$39.2M Buy
169,096
+1,447
+0.9% +$295K 2.38% 9
2025
Q2
$31.1M Sell
167,649
-3,144
-2% -$584K 2.06% 14
2025
Q1
$35.8M Sell
170,793
-3,669
-2% -$713K 2.7% 10
2024
Q4
$31M Buy
174,462
+2,721
+2% +$500K 2.16% 13
2024
Q3
$33.9M Buy
171,741
+845
+0.5% +$158K 2.47% 11
2024
Q2
$29.3M Buy
170,896
+1,389
+0.8% +$230K 2.26% 11
2024
Q1
$30.9M Buy
169,507
+857
+0.5% +$148K 2.54% 8
2023
Q4
$26.1M Sell
168,650
-2,435
-1% -$355K 2.42% 9
2023
Q3
$25.5M Sell
171,085
-1,999
-1% -$293K 2.65% 6
2023
Q2
$23.4M Sell
173,084
-5,698
-3% -$836K 2.37% 7
2023
Q1
$28.5M Sell
178,782
-919
-0.5% -$141K 3.06% 4
2022
Q4
$29M Sell
179,701
-133
-0.1% -$20.4K 3.34% 4
2022
Q3
$24.1M Buy
179,834
+1,867
+1% +$268K 2.94% 5
2022
Q2
$27.3M Sell
177,967
-1,497
-0.8% -$229K 3.34% 5
2022
Q1
$29.1M Sell
179,464
-862
-0.5% -$125K 2.83% 6
2021
Q4
$24.4M Buy
180,326
+1,301
+0.7% +$154K 2.27% 7
2021
Q3
$19.3M Buy
179,025
+4,298
+2% +$491K 2.01% 9
2021
Q2
$19.7M Buy
174,727
+7,380
+4% +$831K 2.07% 9
2021
Q1
$18.1M Buy
167,347
+9,096
+6% +$973K 2.2% 7
2020
Q4
$17M Buy
158,251
+17,929
+13% +$1.72M 2.23% 7
2020
Q3
$12.3M Buy
140,322
+10,466
+8% +$985K 1.83% 12
2020
Q2
$12.7M Buy
129,856
+34,236
+36% +$3.01M 2.18% 9
2020
Q1
$7.29M Buy
95,620
+4,075
+4% +$347K 1.54% 19
2019
Q4
$8.11M Buy
91,545
+6,600
+8% +$548K 1.33% 23
2019
Q3
$6.43M Buy
84,945
+9,147
+12% +$627K 1.16% 30
2019
Q2
$5.51M Sell
75,798
-3,260
-4% -$256K 1.03% 36
2019
Q1
$6.37M Sell
79,058
-6,832
-8% -$559K 1.24% 27
2018
Q4
$7.92M Sell
85,890
-613
-0.7% -$53.9K 1.75% 20
2018
Q3
$8.18M Buy
86,503
+1,128
+1% +$107K 1.53% 22
2018
Q2
$7.91M Sell
85,375
-3,999
-4% -$391K 1.57% 24
2018
Q1
$8.46M Sell
89,374
-5,589
-6% -$614K 1.75% 19
2017
Q4
$9.18M Sell
94,963
-3,953
-4% -$373K 1.94% 17
2017
Q3
$8.79M Sell
98,916
-1,447
-1% -$110K 1.92% 18
2017
Q2
$7.28M Sell
100,363
-1,149
-1% -$77.2K 1.65% 21
2017
Q1
$6.61M Sell
101,512
-2,447
-2% -$154K 1.52% 21
2016
Q4
$6.51M Sell
103,959
-3,752
-3% -$229K 1.62% 17
2016
Q3
$6.79M Buy
107,711
+300
+0.3% +$19.4K 1.72% 17
2016
Q2
$6.65M Buy
107,411
+5,496
+5% +$335K 1.74% 15
2016
Q1
$5.82M Buy
101,915
+125
+0.1% +$6.97K 1.57% 22
2015
Q4
$6.03M Buy
101,790
+24,900
+32% +$1.43M 1.62% 18
2015
Q3
$4.18M Buy
76,890
+4,317
+6% +$281K 1.23% 33
2015
Q2
$4.88M Buy
72,573
+9,385
+15% +$613K 1.26% 24
2015
Q1
$3.7M Sell
63,188
-6,896
-10% -$417K 0.97% 38
2014
Q4
$4.59M Buy
70,084
+7,720
+12% +$487K 1.25% 26
2014
Q3
$3.52M Hold
62,364
0.97% 36
2014
Q2
$3.52M Buy
62,364
+6,325
+11% +$332K 0.97% 36
2014
Q1
$2.88M Buy
56,039
+12,300
+28% +$622K 0.85% 44
2013
Q4
$2.31M Sell
43,739
-300
-0.7% -$14.7K 0.72% 48
2013
Q3
$1.97M Buy
44,039
+5,049
+13% +$224K 0.55% 49
2013
Q2
$1.61M Buy
+38,990
New +$1.71M 0.58% 54

Other funds holding ABBV

Adell Harriman & Carpenter's ABBV Position: Q2 2026 in Review

Adell Harriman & Carpenter increased its AbbVie (ABBV) stake by 0.5% in Q2 2026, buying an estimated $184K and bringing the position to 170,667 shares worth $42.9M. The position accounts for 2.2% of the portfolio, ranked #10.

Adell Harriman & Carpenter first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Adell Harriman & Carpenter held 170,667 shares of AbbVie worth $42.9M as of Q2 2026.
  • Adell Harriman & Carpenter bought 855 AbbVie shares in Q2 2026, an estimated $184K.
  • AbbVie made up 2.2% of Adell Harriman & Carpenter's portfolio in Q2 2026, its #10 holding.
  • Adell Harriman & Carpenter first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Adell Harriman & Carpenter's 13F filing for Q2 2026, filed 4 Aug 2026.